Prednisone side effects: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Protected "Prednisone side effects": Excessive spamming ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{CMG}} | {{CMG}} | ||
== | ==List of side effects== | ||
<font size="4">[[Prednisone side effects#Fluid and Electrolyte Disturbances|Fluid and Electrolyte Disturbances]]</font> | <font size="4">[[Prednisone side effects#Fluid and Electrolyte Disturbances|Fluid and Electrolyte Disturbances]]</font> | ||
<br> | <br> | ||
| Line 31: | Line 31: | ||
*Potassium loss | *Potassium loss | ||
*Hypokalemic alkalosis | *Hypokalemic alkalosis | ||
*Hypertension ''[[Prednisone side effects# | *Hypertension ''[[Prednisone side effects#List of side effects|Return to top]]'' | ||
<br> | <br> | ||
=== Musculoskeletal=== | === Musculoskeletal=== | ||
| Line 39: | Line 39: | ||
*Osteoporosis | *Osteoporosis | ||
*Vertebral compression fractures | *Vertebral compression fractures | ||
*Aseptic necrosis of femoral and humeral heads ''[[Prednisone side effects# | *Aseptic necrosis of femoral and humeral heads ''[[Prednisone side effects#List of side effects|Return to top]]'' | ||
<br> | <br> | ||
===Gastrointestinal=== | ===Gastrointestinal=== | ||
| Line 45: | Line 45: | ||
*Pancreatitis | *Pancreatitis | ||
*Abdominal distention | *Abdominal distention | ||
*Ulcerative esophagitis ''[[Prednisone side effects# | *Ulcerative esophagitis ''[[Prednisone side effects#List of side effects|Return to top]]'' | ||
<br> | <br> | ||
===Dermatologic=== | ===Dermatologic=== | ||
| Line 53: | Line 53: | ||
*Facial erythema | *Facial erythema | ||
*Increased sweating | *Increased sweating | ||
*May suppress reactions to skin tests ''[[Prednisone side effects# | *May suppress reactions to skin tests ''[[Prednisone side effects#List of side effects|Return to top]]'' | ||
<br> | <br> | ||
===Neurological=== | ===Neurological=== | ||
| Line 59: | Line 59: | ||
*Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment | *Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment | ||
*Vertigo | *Vertigo | ||
*Headache ''[[Prednisone side effects# | *Headache ''[[Prednisone side effects#List of side effects|Return to top]]'' | ||
<br> | <br> | ||
===Endocrine=== | ===Endocrine=== | ||
| Line 68: | Line 68: | ||
*Decreased carbohydrate tolerance | *Decreased carbohydrate tolerance | ||
*Manifestations of latent diabetes mellitus | *Manifestations of latent diabetes mellitus | ||
*Increased requirements for insulin or oral hypoglycemic agents in diabetics ''[[Prednisone side effects# | *Increased requirements for insulin or oral hypoglycemic agents in diabetics ''[[Prednisone side effects#List of side effects|Return to top]]'' | ||
<br> | <br> | ||
===Ophthalmic=== | ===Ophthalmic=== | ||
| Line 74: | Line 74: | ||
*Increased intraocular pressure | *Increased intraocular pressure | ||
*Glaucoma | *Glaucoma | ||
*Exophthalmos ''[[Prednisone side effects# | *Exophthalmos ''[[Prednisone side effects#List of side effects|Return to top]]'' | ||
<br> | <br> | ||
===Metabolic=== | ===Metabolic=== | ||
Negative nitrogen balance due to protein catabolism ''[[Prednisone side effects# | Negative nitrogen balance due to protein catabolism ''[[Prednisone side effects#List of side effects|Return to top]]'' | ||
<br> | <br> | ||
---- | ---- | ||
<br> | |||
<br> | <br> | ||
{{FDA}} | {{FDA}} | ||
Latest revision as of 13:08, 19 December 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
List of side effects
Fluid and Electrolyte Disturbances
Musculoskeletal
Gastrointestinal
Dermatologic
Neurological
Endocrine
Ophthalmic
Metabolic
Fluid and Electrolyte Disturbances
- Sodium retention
- Fluid retention
- Congestive heart failure in susceptible patients
- Potassium loss
- Hypokalemic alkalosis
- Hypertension Return to top
Musculoskeletal
- Muscle weakness
- Steroid myopathy
- Loss of muscle mass
- Osteoporosis
- Vertebral compression fractures
- Aseptic necrosis of femoral and humeral heads Return to top
Gastrointestinal
- Peptic ulcer with possible perforation and hemorrhage
- Pancreatitis
- Abdominal distention
- Ulcerative esophagitis Return to top
Dermatologic
- Impaired wound healing
- Thin fragile skin
- Petechiae and ecchymoses
- Facial erythema
- Increased sweating
- May suppress reactions to skin tests Return to top
Neurological
- Convulsions
- Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment
- Vertigo
- Headache Return to top
Endocrine
- Menstrual irregularities
- Development of cushingoid state
- Suppression of growth in children
- Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness
- Decreased carbohydrate tolerance
- Manifestations of latent diabetes mellitus
- Increased requirements for insulin or oral hypoglycemic agents in diabetics Return to top
Ophthalmic
- Posterior subcapsular cataracts
- Increased intraocular pressure
- Glaucoma
- Exophthalmos Return to top
Metabolic
Negative nitrogen balance due to protein catabolism Return to top
Adapted from the FDA Package Insert.